Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Total Non-Current Liabilities data on file, last reported at $55.5 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 51.33% year-over-year to $55.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (down 51.33% YoY) and the FY2025 annual result came in at $56.9 million, down 71.97% from the prior year.
• Total Non-Current Liabilities fell to $55.5 million in Q1 2026, from $56.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $260.1 million in Q4 2023 to a low of $31.2 million in Q2 2025.
• A 5-year average of $174.4 million and a median of $203.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 40.11% — and 2025, when it plunged 86.09%.
• Tracing ATRA's Total Non-Current Liabilities over 5 years: stood at $244.2 million in 2022, then grew by 6.51% to $260.1 million in 2023, then declined by 21.91% to $203.1 million in 2024, then slumped by 71.97% to $56.9 million in 2025, then declined by 2.57% to $55.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $55.5 million (Q1 2026), $56.9 million (Q4 2025), and $65.0 million (Q3 2025), per Business Quant data.